Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Photodiagnosis Photodyn Ther ; 40: 103174, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36602069

ABSTRACT

BACKGROUND: Photodynamic therapy (PDT) is used to treat tumors through selective cytotoxic effects. PDT induces damage-associated molecular patterns (DAMPs) expression, which can cause an immunogenic death cell (IDC). In this study we identified potential immunogenic epitopes generated by PDT on triple-negative breast cancer cell line (MDA-MB-231). METHODS: MDA-MB-231 cells were exposed to PDT using ALA (160 µg/mL)/630 nm at 8 J/cm2. Membrane proteins were extracted and separated by 2D PAGE. Proteins overexpressed were identified by LC-MS/MS and analyzed in silico through a peptide-HLA docking in order to identify the epitopes with more immunogenicity and antigenicity properties, as well as lower allergenicity and toxicity activity. The selected peptides were evaluated in response to macrophage activation and cytokine release by flow cytometry. RESULTS: Differential proteins were overexpressed in the cells treated with PDT. A group of 16 peptides were identified from them, established in a rigorous selection by measuring antigenicity, immunogenicity, allergenicity, and toxicity in silico. The final selection was based on molecular dynamics, where 2 peptides showed the highest stability regarding to the RMSD value. These peptides were obtained from the proteins calreticulin and HSP90. The cytokine analysis evidenced macrophage activation by the releasing of TNF. CONCLUSION: Two peptides were identified from calreticulin and HSP90; proteins induced by PDT in MDA-MB-231 cells. Both epitopes showed immunogenic potential as a peptide-based vaccine for triple-negative breast cancer.


Subject(s)
Breast Neoplasms , Photochemotherapy , Triple Negative Breast Neoplasms , Vaccines , Humans , Female , Photosensitizing Agents , Photochemotherapy/methods , Calreticulin/metabolism , Calreticulin/therapeutic use , Epitopes/therapeutic use , Triple Negative Breast Neoplasms/drug therapy , Chromatography, Liquid , Tandem Mass Spectrometry , Vaccines/therapeutic use , Cytokines/metabolism , Cell Line, Tumor
2.
Infect Immun ; 60(1): 154-8, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1370271

ABSTRACT

The major surface antigen p190 of the human malaria parasite Plasmodium falciparum contains nonpolymorphic, immunogenic stretches of amino acids which are attractive components for a subunit vaccine against malaria. One such polypeptide, termed 190L, is contained in the 80-kDa processing product of p190, which constitutes the major coat component of mature merozoites. We report here that immunization of Aotus monkeys with 190L gives only poor protection against P. falciparum challenge. However, addition by genetic engineering of a universal T-cell epitope (CS.T3) to 190L improved immunity, and as a result three of four monkeys were protected following challenge infection with blood-stage parasites. Neither antibody against the immunizing antigens or against blood-stage parasites nor the capacity of the monkeys' sera to inhibit in vitro parasite invasion correlated with protection. However, in contrast to sera from nonprotected monkeys, sera from protected animals contained elevated levels of gamma interferon. These results suggest that gamma interferon is directly or indirectly involved in the process of asexual parasite control in vivo.


Subject(s)
Antigens, Surface/therapeutic use , Epitopes/therapeutic use , Interferon-gamma/blood , Malaria/prevention & control , Protozoan Proteins/therapeutic use , Recombinant Proteins/therapeutic use , Animals , Antibody Formation , Aotus trivirgatus , Base Sequence , Immunization, Passive , Molecular Sequence Data , Plasmids
SELECTION OF CITATIONS
SEARCH DETAIL